Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Asahi discloses anxiolytic/cognition-enhancing drugs

May 3, 1996

Eisai returns sumatriptan rights to Glaxo Wellcome

May 3, 1996

Phase III data for Quadramet presented at ASCO

May 3, 1996

Zambon claims (S)-ibuprofen composition

May 3, 1996

Droxidopa studied in patients with chronic pain

May 3, 1996

MM-218 selected for development in emesis, diarrhea

April 26, 1996

Promising clinical results reported for CRF

April 26, 1996

NMDA/glycine-site antagonists revealed by RPR

April 26, 1996

Lilly claims mGluR antagonists for neurodegeneration

April 26, 1996

OPC-14523 improves learning in preclinical models

April 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...